Trefis reported that faster sales growth in Gilead’s HIV drug segment was an early indicator cited by management as far back as February 2025. Regulatory filings showed revenue pickup throughout 2025. Revenue grew at a double-digit rate in the quarter ended June 2026, though the digest provides no exact growth rate or dollar amount.
Key facts
Regulatory filings showed revenue pickup throughout 2025, culminating in double-digit growth in the quarter ending June 2026. source
Gilead management highlighted faster sales growth, particularly in its HIV drug segment, as early as February 2025. source